Bora Pharmaceuticals Co (保瑞藥業) is still looking at contract development and manufacturing organizations (CDMOs) as potential merger and acquisition (M&A) targets, as the company continues to expand its business scale, the medicine and healthcare product maker said yesterday.
The company has seen its market value surge by more than 50-fold in seven years through a series of strategic M&As, including acquiring Japan-based Eisai Co’s subsidiary and plant in Tainan’s Guantian District (官田) in 2013 and US-based Impax Laboratories Inc’s subsidiary and plant in Miaoli County’s Jhunan Township (竹南) in 2018.
“We expect to see new M&A opportunities emerge next year,” Chinese-language online news outlet Cnyes.com quoted Bora Pharmaceuticals chairman Bobby Sheng (盛保熙) as saying. “There are not many buyers in the US M&A market and the valuations of many CDMOs are much cheaper than before, which is relatively beneficial to us.”
Photo: CNA
Sheng made the remarks at a ceremony at the Taiwan Stock Exchange (TWSE), where the company made its share debut on the main board after transferring its listing from the Taipei Exchange.
Bora Pharmaceuticals shares fell 3.1 percent to close at NT$657, in line with losses across the main exchange. Prior to yesterday, the stock had surged more than 60 percent since the beginning of this year.
Due to the growing market demand for drugs, several major clients have already discussed placing more orders, Bora Pharmaceuticals said.
As a result, the company has furthered its acquisition efforts, including factories, companies and product portfolios, it said.
It would also continue to adjust product strategy at its subsidiary TWi Pharmaceuticals Inc (安成藥) in a bid to diversify away from generic drugs, after the unit in August acquired six brand product licenses and technologies from Morristown, New Jersey-based Almatica Pharma Inc, it said.
The new strategy would enable Bora to leverage its sales platforms to enter the brand product market, create a new revenue driver and improve its profit margin, as well as allow the company to have more resources for future investment, it said.
Bora Pharmaceuticals’ consolidated revenue grew 50.25 percent year-on-year to NT$13.25 billion (US$422.5 million) in the first 11 months of this year, ranking second among Taiwanese pharmaceutical companies, TWSE data showed.
Net profit in the first three quarters totaled NT$2.47 billion, up 149.43 percent from the same period last year, with earnings per share rising from NT$10.12 to NT$24.63 and gross margin improving from 35.02 percent to 48.16 percent, the data showed.
HORMUZ ISSUE: The US president said he expected crude prices to drop at the end of the war, which he called a ‘minor excursion’ that could continue ‘for a little while’ The United Arab Emirates (UAE) and Kuwait started reducing oil production, as the near-closure of the crucial Strait of Hormuz ripples through energy markets and affects global supply. Abu Dhabi National Oil Co (ADNOC) is “managing offshore production levels to address storage requirements,” the company said in a statement, without giving details. Kuwait Petroleum Corp said it was lowering production at its oil fields and refineries after “Iranian threats against safe passage of ships through the Strait of Hormuz.” The war in the Middle East has all but closed Hormuz, the narrow waterway linking the Persian Gulf to the open seas,
RATIONING: The proposal would give the Trump administration ample leverage to negotiate investments in the US as it decides how many chips to give each country US officials are debating a new regulatory framework for exporting artificial intelligence (AI) chips and are considering requiring foreign nations to invest in US AI data centers or security guarantees as a condition for granting exports of 200,000 chips or more, according to a document seen by Reuters. The rules are not yet final and could change. They would be the first attempt to regulate the flow of AI chips to US allies and partners since US President Donald Trump’s administration said it rescinded its predecessor’s so-called AI diffusion rules. Those rules sought to keep a significant amount of AI
Apple Inc increased iPhone production in India by about 53 percent last year and now makes a quarter of its marquee devices there, reflecting the US company’s efforts to avoid tariffs on China. The company assembled about 55 million iPhones in India last year, up from 36 million a year earlier, people familiar with the matter said, asking not to be named because the numbers aren’t public. Apple makes about 220 million to 230 million iPhones a year globally, with India’s share of the total increasing rapidly. Apple has accelerated its expansion in the world’s most populous country in recent years, bolstered
A new worry has been rippling across the stock market lately: Entire businesses, not just their employees, might be thrown out of work. While most economists say fears of an artificial intelligence (AI) job apocalypse are overblown, seismic shifts have happened in the past after big tech breakthroughs. The IT revolution of the 1990s led to a surge in productivity that sped up the US economy for several years. It also rendered companies or even industries largely redundant — from travel agents and stockbrokers to classified advertising and newspapers, or video rental stores. Economists expect AI would deliver higher productivity,
RSS